To include your compound in the COVID-19 Resource Center, submit it here.

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Alimera Sciences Inc. (NASDAQ:ALIM) was off $0.04 to $8.36 on Friday after the company resubmitted an NDA to FDA for Iluvien to treat diabetic macular edema. According to Alimera, FDA indicated that the NDA will be classified as a Class 2 resubmission, with a six-month review. In December, the agency issued a complete response letter asking for additional analyses of safety and efficacy data through month 36 from the two Phase III FAME trials of Iluvien.

Alimera lost $0.07 on the week. It has rights to Iluvien from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), which lost $0.03 to $3.85 on Friday and off $0.35 on the week.

BioMimetic Therapeutics Inc. (NASDAQ:BMTI) lost $5.19 (39%) to $8.11 last week despite FDA's Orthopedic and Rehabilitation Devices Panel voting 10-8 on Thursday that the benefits of Augment Bone Graft to treat foot and ankle fractures outweighed its risks as an alternative to autograft. BioMimetic shares had fallen $4.73 (35%) to $8.66 on Tuesday after FDA released briefing documents

Read the full 1628 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers